Thanks to Lesly Maranan, for passing this along!
From the desk of Dan Ollendorf, MPH, ARM, Chief Review Officer, Institute for Clinical & Economic Review
I am writing concerning the efforts of a new initiative known as the Institute for Clinical & Economic Review (ICER), a new initiative of Harvard Medical School, that seeks to provide an impartial review of new or emerging healthcare technologies that involves ALL relevant stakeholders (including patients). We are currently evaluating permanent brachytherapy and proton beam therapy for prostate cancer, and would like to include patients who have undergone each of these treatments in our discussion.
While our reviews operate on an 8-month cycle, the time commitment we would need includes an initial, one-hour conference call, review of documents produced during the review cycle at your discretion, and attendance at all or part (again, at your discretion) of a live one-day meeting in the Boston area. You will be compensated for your time.
Additional note: The menu at the site has a staff icon and from there you can email Dan Ollendorf, directly.
“Launched in 200, ICER is an academic technology assessment initiative based at Harvard Medical School. ICER produces rigorous assessments of new medical interventions and translates its findings into integrated ratings specifically formatted to support value-based insurance benefit designs, coverage and reimbursement policy, and patient-clinician decision support tools.”